-
Cryptosporidium AdhE: Imidazole Inhibition and Efficacy
2026-08-16
The reference study establishes the bacterial-type bifunctional aldehyde/alcohol dehydrogenase CpAdhE as a chemically tractable target in Cryptosporidium parvum. Screening and follow-up experiments connect lower-micromolar enzyme inhibition by selected antifungal imidazoles with suppression of parasite growth in vitro, while also defining important limits for target validation and therapeutic translation.
-
RIPostC, Ketone Bodies, and Ferroptosis in Stroke
2026-08-15
This ACS Chemical Neuroscience study identifies ketone body metabolism as a mechanistic link between remote ischemic postconditioning and neuroprotection after ischemic stroke. Rat and neuronal-cell experiments connect the intervention with improved energy status, reduced iron-dependent lipid peroxidation, preservation of GPX4, and suppression of ACSL4, while also defining important limits for translating ketone-body findings into metabolite-specific studies.
-
Norovirus Co-opts NINJ1 for Selective Secretion
2026-08-14
Song and colleagues show that murine norovirus uses NINJ1-mediated plasma membrane rupture as part of an unconventional, selective route for releasing the viral protein NS1. The study connects caspase-3 cleavage, NINJ1 recruitment to viral replication sites, and NS1–NINJ1 interaction, while demonstrating that this pathway contributes to oral infection in mice.
-
iPSC Trial Selection for Ultrarare Disease
2026-08-14
The reference study developed a patient-specific iPSC platform to prescreen therapies for an ultrarare ECHS1-related Leigh-like syndrome before further clinical-trial decisions. Its key contribution is a multisystem, control-based workflow that connected cellular drug responses with a subsequent three-year patient treatment experience, while also clarifying the limits of extrapolating results across genetically distinct disorders.
-
CPI-613 Workflows for Cancer Metabolism Studies
2026-08-13
Build reproducible tumor cell metabolism studies around CPI-613 with dose–time pilots, orthogonal mitochondrial readouts, and combination-testing strategies. The workflow also translates recent cholangiocarcinoma findings into practical assays for PDHA1 activity, α-ketoglutarate accumulation, apoptosis, and macrophage antigen presentation.
-
Ceruletide: Designing Better Pancreatic Fibrosis Assays
2026-08-13
Ceruletide, also known as Caerulein, is more than a secretagogue: it is a controllable physiological input for connecting pancreatic injury models with fibrosis biology. This guide explains how to use its receptor-driven effects, product specifications, and mechanistic study design to improve pancreatic function research and assay interpretation.
-
Sumatriptan Metabolism: CYP and MAO Revisited
2026-08-12
The reference study challenges the prevailing view that sumatriptan is metabolized mainly through MAO A-mediated oxidative deamination. Using recombinant human enzymes and HPLC–MS, it identifies CYP1A2, CYP2C19, and CYP2D6 as contributors to sequential N-demethylation, while confirming selective MAO A activity toward the parent drug and its desmethyl metabolites.
-
Syringin Enhances Sunitinib in Renal Cell Carcinoma
2026-08-12
A 2024 study identifies syringin as a potential adjunct to sunitinib in renal cell carcinoma (RCC), combining network pharmacology, molecular docking, cell-based assays, and Western blot analysis to connect phenotype with EGFR/PI3K/Akt signaling. The findings suggest a rationale for studying natural-product combinations in sunitinib-resistant RCC, while the available evidence remains preclinical and requires validation in more physiologically representative models.
-
Sodium Nitroprusside in Sex-Informed Hypertension
2026-08-11
A translational framework for using Sodium Nitroprusside as a nitric oxide donor to separate vascular smooth muscle responsiveness from sex-dependent hemodynamic and autonomic mechanisms in angiotensin II hypertension models.
-
Flumequine: DNA Topoisomerase II Assay Guide
2026-08-11
Flumequine provides a mechanistically focused way to study DNA topoisomerase II inhibition alongside cell-growth arrest and cell killing. This workflow guide shows how to connect enzyme assays, DNA replication research, and time-resolved cancer drug-response measurements while avoiding common interpretation errors.
-
Cefodizime for AMR Research Workflows
2026-08-10
Build reproducible susceptibility, resistance-surveillance, and host-response assays around Cefodizime, a third-generation cephalosporin antibiotic. This workflow connects PBP-directed killing with the urban-rodent Escherichia coli findings from Hanoi while emphasizing controls, resistance boundaries, and practical troubleshooting.
-
Ceruletide Workflows for Pancreatic Research
2026-08-09
Ceruletide, also known as Caerulein, provides a controlled CCK-receptor challenge for pancreatic, gastrointestinal, and smooth-muscle experiments. This guide connects practical peptide handling with fibrosis-focused assays inspired by recent stem-cell, extracellular-vesicle, and nanomedicine research.
-
IBDV VP3 Disrupts IRF7 to Promote Viral Replication
2026-08-08
Wang et al. identify an immune-evasion mechanism in which the infectious bursal disease virus VP3 protein interacts with IRF7 and promotes its proteasome-associated degradation, weakening type I interferon signaling. The findings link loss of IRF7 activity to enhanced viral replication and provide a mechanistic framework for studying virulence differences between very virulent and attenuated IBDV strains.
-
DIDS: From Chloride Transport to Metastatic State Biology
2026-08-07
DIDS is more than a chloride channel blocker: it is a translational probe for testing how membrane transport, cell survival, ER stress, and prometastatic states intersect. This article connects DIDS pharmacology with PAME biology while defining practical validation strategies and important limits.
-
Lactate-Mediated H3K18la Axis Drives Immune Resistance in HC
2026-08-07
This study uncovers how lactate-induced histone H3K18 lactylation in hepatocellular carcinoma (HCC) activates a KIF20A–c-Myc–PD-L1 signaling axis that promotes immune evasion and resistance to PD-1 blockade. The mechanism is shown to be reversible via glycolysis inhibition, highlighting a druggable metabolic-epigenetic pathway with translational potential.